Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21082025 | 0.75 | NUDT1 (0.59) | NUDT1TLR7AHCY | |
| SCHEMBL17505391 | 0.73 | NUDT1 (0.57) | NUDT1TLR7 | |
| SCHEMBL335977 | 0.73 | NUDT1 (0.58) | NUDT1ADORA2AL3MBTL1SMPD3 | |
| SCHEMBL15688262 | 0.72 | NUDT1 (0.55) | NUDT1ADORA2AL3MBTL1 | |
| SCHEMBL5477688 | 0.72 | NUDT1 (0.55) | NUDT1ADORA2AL3MBTL1 | |
| SCHEMBL14381039 | 0.72 | NUDT1 (0.55) | NUDT1ADORA2AL3MBTL1 | |
| SCHEMBL9080834 | 0.72 | NUDT1 (0.55) | NUDT1ADORA2ATLR7L3MBTL1 | |
| SCHEMBL5496407 | 0.72 | NUDT1 (0.56) | NUDT1SMPD3 | |
| Hydrochloric Acid SCHEMBL8374910 | 0.72 | NUDT1 (0.56) | NUDT1ADORA2AL3MBTL1SMPD3 | |
| SCHEMBL17505363 | 0.70 | NUDT1 (0.54) | NUDT1ADORA2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-20090274626-A1 | TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-05 | — | — | US | claimed |
| WO-2007016597-A2 | TARGETING TNF-ALPHA CONVERTING ENZYME (TACE)-DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-08 | — | — | WO | claimed |
| US-5028605-A | Antispasmodic, bronchodilators, uterine relaxants, cardiac analeptics, neurosedatives | L'UNIVERSITE DE MONTPELLIER I (FR) | 1991-07-02 | — | — | US | claimed |
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4638454-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | Celgene Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4562012-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562013-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS IRAK3 BINDERS | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119894513-A | Heterocycles as modulators of NSD activity | 德州大学系统董事会 | 2025-04-25 | — | — | CN | disclosed |
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | Kronos Bio, Inc. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004022562-A1 | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2003-11-13 | — | — | US | disclosed |
| WO-2003089434-A2 | IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-5028605-A | Antispasmodic, bronchodilators, uterine relaxants, cardiac analeptics, neurosedatives | L'UNIVERSITE DE MONTPELLIER I (FR) | 1991-07-02 | — | — | US | disclosed |
| EP-0348392-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | Université Montpellier I (FR) | 1990-01-03 | — | — | EP | disclosed |
| WO-1988004298-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, PRKACA, MAP3K1 | NUDT1 995/4885ADORA2A 1225/4885TLR7 2271/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | NUDT1 3219/4885ADORA2A 2358/4885TLR7 2121/4885 |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | NUDT1 4273/4885ADORA2A 4632/4885TLR7 2166/4885 |
| US-12263163-B2 | Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor | SYK, LCK, LYN | NUDT1 4268/4885ADORA2A 4307/4885TLR7 85/4885 |
| US-20030212073-A1 | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | PRKACA, MAP3K8, MAP3K1 | NUDT1 820/4885ADORA2A 1231/4885TLR7 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.